Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 4 1Phase 3 1

Status

Completed 36Unknown 7Terminated 4Recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 16Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5Neoplasm Metastasis 5Glioblastoma 5Colonic Neoplasms 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Polycystic Ovary Syndrome 4Lymphoma, Follicular 4Fallopian Tube Neoplasms 4

Interventions

Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Vomiting × Clear all
NCT07035821 2025-06-25

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

Shanghai Children's Medical Center

Phase 3 Not yet recruiting
100 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡